E25-RIVAL Study: Ranibizumab vs Aflibercept in T&E for wet AMD- Dr. Mark Gillies
The Retina Channel Podcast · Keyvan Koushan
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr. Mark Gillies from Sydney, Australia discusses 2-year results of the RIVAL Study which investigated rates of geographic atrophy and visual acuity changes in patients with wet AMD.
Full reference:
Gillies, M. C., Hunyor, A. P., Arnold, J. J., Guymer, R. H., Wolf, S., Ng, P., . . . McAllister, I. L. (2019). Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.6776